Gujarat Terce Laboratories Limited · BSE:GUJTERC
Gujarat Terce Laboratories — Q1 FY23 Earnings Presentation
11 slides from Gujarat Terce Laboratories's earnings presentation, August 2022
Slide 1: Gujarat Terce Laboratories Limited
GUJARAT TERCE 44 LABORATORIES LIMITED
Slide 2: Disclaimer
Disclaimer This presentation is for informational purposes only and does not constitute an offer or a solicitation to sell or an edition or a solicitation to submit an offer to purchase or subscribe for shares or securities of Gujarat Terce Laboratories Limited or a portion thereof, constitute the b
Slide 3: Company Overview
Company Overview Gujarat Terce has over 3 decades of experience in the Manufacturing and Marketing of branded Generics. Roots of Gujarat Terce Laboratories Limited are entrenched in the founding principles of COMPASSION and EXCELLENCE. Terce has an extensive basket of 50 Brands (125 products) with a
Slide 4: Business Highlights
Business Highlights Figures= % of total sales Figures= % of total sales 100 64 81 Q1FY22 36 79 79 77 75 70 Acute Segment 63 Other Brands Q2FY22 37 Chronic Segment Precious Brands 50 64 Q3FY22 36 30 61 25 21 21 23 Q4FY22 39 19 56 Q1FY23 44 0 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 0 25 50 75 As per AICOD
Slide 5: Business Highlights- PCPM (Per Capita Per Month)
Business Highlights- PCPM (Per Capita Per Month) 2 1.92 1.87 1.75 1.63 1.5 Our product portfolio having 1.42 majorly acute brands, is cyclical in revenue, thus resulting in a subdued 1 Q1 The geographical expansion across the country, resulting increase in 0.5 headcount, reflects in a lower PCPM in
Slide 6: Business Highlights- Sales of Top Four Brands
Business Highlights- Sales of Top Four Brands Figures in lacs 300 100 93 266 86 208 75 204 69 200 161 56 57 50 117 100 25 0 0 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Therapeutic Segment- Anticold Therapeutic Segment- Pain Management Type- Acute Type- Acute
Slide 7: Business Highlights- Sales of Top Four Brands
Business Highlights- Sales of Top Four Brands Figures in lacs 125 800 79 103 100 600 54 53 50 50 75 67 400 50 29 25 25 25 200 0 0 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Therapeutic Segment- Nutraceutical Therapeutic Segment- Vitamins ( Nutraceuticals) Type- Acute Type-
Slide 8: Distribution Network & Region Wise Sales
Distribution Network & Region Wise Sales North 17 29.6% 6 105 139 28 West 75 75 50.3% 12 1 18 1 3 Central 20.1% 1 Stockists/ Region-wise sales distribution(Q1FY23) Distributors
Slide 9: Financial Highlights- Q1 FY23
Financial Highlights- Q1 FY23 -5% -195% -218% Q1FY23 YoY growth Op Revenue EBIDTA PAT As per AICOD data, the Q1FY23 growth of IPM (Indian Pharmaceutical Market) is 2.1%. Gujarat Terce has declined by 5% in Q1FY23. Cash Profit registered by business has decreased by 210% in Q1FY23.
Slide 10: Q1 FY23 Income Statement
Q1IFY23- INCOME STATEMENT Particulars Revenue from Operations EBDITA EBDITA(% of Net Sales) PBT PBT(% of Net Sales) PAT (Before OCI) PAT(% of Net Sales) Cash Profit /(Loss) Cash Profit (% of Net Sales) Basic/Diluted EPS (in Rs.) 941.35 161.56 -17.16% 188.32 -20.01% -188.32 -20.01% 181.42 -19.27% 2.5
Slide 11: Thank you.
Thank you. Registered Office: Gujarat Terce Laboratories Limited, 122/2 Ravi estate, Bileshwarpura, Chhatral, T.A.: Kalol, Gandhinagar, Gujarat 382729 Corporate office: D/ 801 - 802 & 1202, The First, Behind Keshavbaug party plot, Near Shivalik High- Street, Vastrapur, Ahmedabad, Gujarat 380015 Inve
Gujarat Terce Laboratories — Q1 FY23 Earnings Presentation on 6ix